17a-ethynylestradiol-3-sulfate treatment of severe blood loss in rats

Academic Article

Abstract

  • © 2015 Elsevier Inc. All rights reserved. Background: From 2001-2011, >80% of potentially survivable United States battlefield deaths were due to severe hemorrhage. We subjected male rats to acute severe blood loss, administered a single dose of 17α-ethynylestradiol-3-sulfate (EE-3-SO4) without resuscitative fluids, and measured survival and also mean arterial pressures (MAP). Methods: After controlled removal of 60% circulating blood volume (10-11 μL) over approximately 45 min, rats received EE-3-SO4 at 0 (vehicle controls), 0.1, 0.3, 1.0, or 3.0 mg/ kg in 40 μL/100 g BW saline intravenously. MAP was recorded for 40 min after drug administration and survival was recorded for 6 h. Results: The dose response curve was bell shaped with optimum survival at 1 mg/kg EE-3- SO4. Median survival times of rats receiving 1 mg/kg (360 min) were approximately 6 times that of the control group (57 min): P = 0.0001. The number of animals alive at 6 h was 16 of 20 (80%) in the 1 mg/kg group versus 0 of 20 (0%) in the control group. Early increases in MAP correlated with longer survival times. Conclusions: Administration of a single dose of 1 mg/kg EE-3-SO4 in 0.4 μL/kg of saline after controlled severe hemorrhage increased survival in rats by 6-fold. Partial recovery of blood pressure values correlated with longer survival time. These results, coupled with similar findings in a companion study in minipigs, support the further product development of EE- 3-SO4 for: (1) severe hemorrhage when standard resuscitative fluids are not available, and (2) situations in which prolonged transportation periods are required for definitive treatment of the injured.
  • Authors

    Digital Object Identifier (doi)

    Author List

  • Hubbard W; Keith J; Berman J; Miller M; Scott C; Peck C; Chaudry IH
  • Start Page

  • 355
  • End Page

  • 360
  • Volume

  • 193
  • Issue

  • 1